Cathy Qi

Articles by Cathy Qi

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

ByPedram Razavi,Judith Balmaña,Stephen Luen,Mario Campone,Laura Cortesi,Norikazu Masuda,Kyong Hwa Park,Qingyuan Zhang,Emily Nizialek,Cathy Qi,Karen Cui,Sibylle Loibl,Mark Robson, MD,Filipa Lynce

April 22nd 2025

Latest Updated Articles

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
April 22nd 2025

Trending on CancerNetwork

BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer

RYZ101 Improves Progression-Free Survival in Previously Treated GEP-NETs

Why CAR T-Cell Therapy Before Bispecifics May Be the Ideal Multiple Myeloma Sequence

Teclistamab Vs Talquetamab After Relapse on CAR T-Cell Therapy in Multiple Myeloma

How Might IMiD Holding Therapy Impact Outcomes in R/R Multiple Myeloma?